ArticleViruses2020
Comparison of CRISPR and Marker-Based Methods for the Engineering of Phage T7.
Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- A novel putative genus phage CW39: implications for CRISPR-Cas9-based phage resistance inFrontiers in microbiology · 2026Article
- Phage Therapy forAntibiotics (Basel, Switzerland) · 2025Review
- CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool.World journal of microbiology & biotechnology · 2025Review
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- PHEIGES: all-cell-free phage synthesis and selection from engineered genomes.Nature communications · 2024Article
- Article
- T7 phage-assisted evolution of riboswitches using error-prone replication and dual selection.Scientific reports · 2024Article
- High-throughput approaches to understand and engineer bacteriophages.Trends in biochemical sciences · 2023Review
- Review
- Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage-bacteria interactions.Frontiers in microbiology · 2023Review
- Advance on Engineering of Bacteriophages by Synthetic Biology.Infection and drug resistance · 2023Review
- Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing.Nature microbiology · 2022Article
- CRISPR-based engineering of phages for in situ bacterial base editing.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Pseudotyping Bacteriophage P2 Tail Fibers to Extend the Host Range for Biomedical Applications.ACS synthetic biology · 2022Article
- Prokaryotic innate immunity through pattern recognition of conserved viral proteins.Science (New York, N.Y.) · 2022Article
- T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Article
- Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- Modification of Bacteriophages to Increase Their Association with Lung Epithelium Cells In Vitro.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Strategies for Bacteriophage T5 Mutagenesis: Expanding the Toolbox for Phage Genome Engineering.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
With the recent rise in interest in using lytic bacteriophages as therapeutic agents, there is an urgent requirement to understand their fundamental biology to enable the engineering of their genomes. Current methods of phage engineering rely on homologous recombination, followed by a system of selection to identify recombinant phages. For bacteriophage T7, the host genes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.